<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500409</url>
  </required_header>
  <id_info>
    <org_study_id>VB006/05</org_study_id>
    <nct_id>NCT00500409</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis</brief_title>
  <official_title>Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis. A Randomized Controlled Open-label Multicentre Study in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virchow Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virchow Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OSTEOFORM, containing recombinant (rhPTH [1-34]), enhances bone mineral density and reduces
      risk for vertebral fracture. This study evaluates the safety and efficacy of OSTEOFORM in the
      treatment of osteoporosis in post-menopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      207 post-menopausal women were enrolled for screening at 6 centres, and supplemented with
      daily 1000 mg elemental calcium and 500 IU of vitamin D for 45 days. 82 eligible women with
      osteoporosis were randomly received daily either calcium and vitamin D alone (control group)
      or Osteoform 20 µg subcutaneously with calcium and vitamin D (drug group) for 12 months. End
      points such as percentage of increase in bone mineral density and, changes in bone biomarkers
      (serum osteocalcin, bone specific alkaline phosphatase, and urinary DPD) were evaluated at
      baseline, and 6 and 12 months after supplementation. Besides, safety parameters and adverse
      events were monitored through out the study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of change in Bone Mineral Density at lumber spine (L1-L4) in postmenopausal women with osteoporosis at the end of 6 and 12 months.</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in biomarkers of bone formation and bone resorption at the end of 3, 6 and 12 months.</measure>
    <time_frame>3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Drug Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osteoform</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SHELCAL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osteoform</intervention_name>
    <description>Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days</description>
    <arm_group_label>Drug Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHELCAL</intervention_name>
    <description>Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Calcium and vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Postmenopausal women with osteoporosis (Lumbar spine or femoral neck BMD or total hip
        T-score less than or equal to-2.5)

        Exclusion Criteria:

          1. Women with vertebral (L1-L4) abnormalities that preclude accurate measurement by DEXA.

          2. Women on medications that are known to affect bone for more than 7 days in the past 6
             months.

          3. Currently taking systemic prednisone, inhaled steroids, anticoagulants,
             anticonvulsants.

          4. History of rhPTH use or known hypersensitivity to study drug.

          5. Vitamin D3 deficiency (Vitamin D3 &lt; 20 ng/ml).

          6. Abnormal thyroid function.

          7. History of kidney disease.

          8. Any history of hypercalciuria, hypercalcemia or hyperparathyroidism.

          9. History of active or treated tuberculosis or significant liver disease or
             gastrointestinal disease or cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Bipin Kumar Sethi, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>CARE Hospitals, Hyderabad, AP, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Manoj Chadha, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. K.Prasanna Kumar, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.S. Ramaiah Medical College, Bangalore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. K.D. Modi, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medwin Hospital, Hyderabad, AP, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Rabinderanath Mehrotra, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Hospitals, Hyderabad, AP, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Usha Sriram, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Hospitals, Chennai, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE Hospitals</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medwin Hospital</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Ramaiah Medical College</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.D. Hinduja Hospital and Medical Research Center</name>
      <address>
        <city>Mumbai</city>
        <state>Maharastra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rhPTH(1-34)</keyword>
  <keyword>Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

